UBS notes the American Society of Oncology abstracts for the company's FOXFIRE/Gloval study shows overall survival rates were not enhanced by Sir-Spheres.
The abstracts are limited in detail and further sub-group analysis may yet reveal differences. UBS has not taken a view on the outcome and its price target relies on existing indications.
Target is $30.30. Buy retained.
Sector: Pharmaceuticals & Biotechnology.
Target price is $30.30.Current Price is $10.75. Difference: $19.55 - (brackets indicate current price is over target). If SRX meets the UBS target it will return approximately 65% (excluding dividends, fees and charges - negative figures indicate an expected loss).
